Choose a country below to begin
- Biological Products Reliance Pathway (decree 343/2021)
- Emergency Use Application & Approval (EUA) - Medicinal Products
- Emergency Use Application & Approval (EUA) - Biological Products
- Reliance pathway for post-approval changes to a registered biotherapeutic product
- EDA-SAHPRA Work Sharing Initiative (WSI) for Registration of Medical Products (Pilot Phase)
- Lot Release of Biological Products in Egypt
- Emergency Use Application & Approval (EUA) - Medicinal Products
- Emergency Use Application & Approval (EUA) - Biological Products
- Reliance pathway for post-approval changes to a registered biotherapeutic product
- EDA-SAHPRA Work Sharing Initiative (WSI) for Registration of Medical Products (Pilot Phase)
- Lot Release of Biological Products in Egypt
- Reliance-based Evaluation Pathways – ABRIDGED REVIEW
- Reliance-based Evaluation Pathways - RECOGNITION
- Reliance-based Evaluation Pathways – VERIFIED REVIEW
- Registration of Candidate COVID-19 vaccines
- EDA-SAHPRA Work Sharing Initiative (WSI) for Registration of Medical Products (Pilot Phase)
- Reliance-based Evaluation Pathways - RECOGNITION
- Reliance-based Evaluation Pathways – VERIFIED REVIEW
- Registration of Candidate COVID-19 vaccines
- EDA-SAHPRA Work Sharing Initiative (WSI) for Registration of Medical Products (Pilot Phase)